Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


11.12.2017

3 AJR Am J Roentgenol
1 Am J Clin Pathol
3 BJU Int
1 BMC Cancer
1 BMC Urol
2 Cancer
1 Cancer Lett
2 Cancer Res
2 Eur Urol
1 Int J Cancer
2 Int J Oncol
1 J Natl Cancer Inst
1 J Urol
1 JAMA
3 Lancet Oncol
1 Nat Rev Urol
1 Oncol Rep
1 PLoS One
1 Urol Int


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. FELKER ER, Raman SS, Margolis DJ, Lu DSK, et al
    Risk Stratification Among Men With Prostate Imaging Reporting and Data System Version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary?
    AJR Am J Roentgenol. 2017 Aug 31:1-6. doi: 10.2214/AJR.17.18008.
    PubMed     Text format     Abstract available

  2. KRISHNA S, McInnes M, Lim C, Lim R, et al
    Comparison of Prostate Imaging Reporting and Data System Versions 1 and 2 for the Detection of Peripheral Zone Gleason Score 3 + 4 = 7 Cancers.
    AJR Am J Roentgenol. 2017 Oct 5:W1-W9. doi: 10.2214/AJR.17.17964.
    PubMed     Text format     Abstract available

  3. NIU XK, Chen ZF, Chen L, Li J, et al
    Clinical Application of Biparametric MRI Texture Analysis for Detection and Evaluation of High-Grade Prostate Cancer in Zone-Specific Regions.
    AJR Am J Roentgenol. 2017 Dec 8:W1-W8. doi: 10.2214/AJR.17.18494.
    PubMed     Text format     Abstract available


    Am J Clin Pathol

  4. SHAH MD, Parwani AV, Zynger DL
    Impact of the Pathologist on Prostate Biopsy Diagnosis and Immunohistochemical Stain Usage Within a Single Institution.
    Am J Clin Pathol. 2017;148:494-501.
    PubMed     Text format     Abstract available


    BJU Int

  5. GREIMAN AK, Rosoff JS, Prasad SM
    Association of Human Development Index with global bladder, kidney, prostate and testis cancer incidence and mortality.
    BJU Int. 2017 May 8. doi: 10.1111/bju.13875.
    PubMed     Text format     Abstract available

  6. HAMMARSTEN J
    Anomalous observation with regard to prostate cancer in cancer research.
    BJU Int. 2017;120:456-457.
    PubMed     Text format    

  7. POON DM, Chan CK, Chan TW, Cheung FY, et al
    Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.
    BJU Int. 2017 Dec 6. doi: 10.1111/bju.14091.
    PubMed     Text format     Abstract available


    BMC Cancer

  8. EGGLY S, Hamel LM, Heath E, Manning MA, et al
    Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials.
    BMC Cancer. 2017;17:807.
    PubMed     Text format     Abstract available


    BMC Urol

  9. AXCRONA K, Nilsson R, Brennhovd B, Sorebo O, et al
    Psychometric properties of the expanded prostate cancer index composite - 26 instrument in a cohort of radical prostatectomy patients: theoretical and practical examinations.
    BMC Urol. 2017;17:111.
    PubMed     Text format     Abstract available


    Cancer

  10. ALIBHAI SMH, Breunis H, Timilshina N, Hamidi MS, et al
    Improving bone health in men with prostate cancer receiving androgen deprivation therapy: Results of a randomized phase 2 trial.
    Cancer. 2017 Dec 6. doi: 10.1002/cncr.31171.
    PubMed     Text format     Abstract available

  11. STEELE CB, Li J, Huang B, Weir HK, et al
    Prostate cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.
    Cancer. 2017;123 Suppl 24:5160-5177.
    PubMed     Text format     Abstract available


    Cancer Lett

  12. CHENG MA, Chou FJ, Wang K, Yang R, et al
    Androgen receptor (AR) degradation enhancer ASC-J9((R)) in an FDA-approved formulated solution suppresses castration resistant prostate cancer cell growth.
    Cancer Lett. 2017 Dec 1. pii: S0304-3835(17)30763.
    PubMed     Text format     Abstract available


    Cancer Res

  13. YOU S, Freeman MR
    A Systems Approach to Prostate Cancer Classification-Response.
    Cancer Res. 2017 Dec 6. pii: 0008-5472.CAN-17-0239.
    PubMed     Text format    

  14. THYSELL E, Ylitalo EB, Jernberg E, Bergh A, et al
    A Systems Approach to Prostate Cancer Classification-Letter.
    Cancer Res. 2017 Dec 6. pii: 0008-5472.CAN-16-3231.
    PubMed     Text format    


    Eur Urol

  15. COOPERBERG MR
    Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer.
    Eur Urol. 2017 Nov 28. pii: S0302-2838(17)30982.
    PubMed     Text format    

  16. HAMDY FC, Lamb AD, Bryant RJ
    Diagnostic Pathways for Screen-detected Prostate Cancer: The Plot Thickens.
    Eur Urol. 2017 Nov 28. pii: S0302-2838(17)30994.
    PubMed     Text format    


    Int J Cancer

  17. UGGE H, Udumyan R, Carlsson J, Andren O, et al
    Acne in late adolescence and risk of prostate cancer.
    Int J Cancer. 2017 Dec 4. doi: 10.1002/ijc.31192.
    PubMed     Text format     Abstract available


    Int J Oncol

  18. EDWARDS DR, Moroz K, Zhang H, Mulholland D, et al
    PRL3 increases the aggressive phenotype of prostate cancer cells in vitro and its expression correlates with high-grade prostate tumors in patients.
    Int J Oncol. 2017 Nov 20. doi: 10.3892/ijo.2017.4208.
    PubMed     Text format     Abstract available

  19. CHEN S, Nimick M, Cridge AG, Hawkins BC, et al
    Anticancer potential of novel curcumin analogs towards castrate-resistant prostate cancer.
    Int J Oncol. 2017 Nov 20. doi: 10.3892/ijo.2017.4207.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  20. WYATT AW, Annala M, Aggarwal R, Beja K, et al
    Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    J Urol

  21. SANDA MG, Cadeddu JA, Kirkby E, Chen RC, et al
    Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline, PART I.
    J Urol. 2017 Dec 1. pii: S0022-5347(17)78003-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    JAMA

  22. MATULEWICZ RS, Weiner AB, Schaeffer EM
    Active Surveillance for Prostate Cancer.
    JAMA. 2017;318:2152.
    PubMed     Text format    


    Lancet Oncol

  23. DUCHESNE GM, Woo HH
    Timing of androgen-deprivation therapy in prostate cancer - Author's reply.
    Lancet Oncol. 2017;18:e635.
    PubMed     Text format    

  24. DEL PRIORE G, Hoffman S
    Timing of androgen-deprivation therapy in prostate cancer.
    Lancet Oncol. 2017;18:e633.
    PubMed     Text format    

  25. NANDAGOPAL L
    Timing of androgen-deprivation therapy in prostate cancer.
    Lancet Oncol. 2017;18:e634.
    PubMed     Text format    


    Nat Rev Urol

  26. STONE L
    Prostate cancer: Stuck in the middle: interstitial genes in TMPRSS2-ERG fusion.
    Nat Rev Urol. 2017 Dec 5. pii: nrurol.2017.208. doi: 10.1038/nrurol.2017.
    PubMed     Text format    


    Oncol Rep

  27. LIU T, Qiu X, Zhao X, Yang R, et al
    Hypermethylation of the SPARC promoter and its prognostic value for prostate cancer.
    Oncol Rep. 2017 Nov 29. doi: 10.3892/or.2017.6121.
    PubMed     Text format     Abstract available


    PLoS One

  28. JEDROSZKA D, Orzechowska M, Hamouz R, Gorniak K, et al
    Markers of epithelial-to-mesenchymal transition reflect tumor biology according to patient age and Gleason score in prostate cancer.
    PLoS One. 2017;12:e0188842.
    PubMed     Text format     Abstract available


    Urol Int

  29. OHLMANN CH, Gross-Langenhoff M
    Efficacy and Tolerability of Leuprorelin Acetate (Eligard(R)) in Daily Practice in Germany: Pooled Data from 2 Prospective, Non-Interventional Studies with 3- or 6-Month Depot Formulations in Patients with Advanced Prostate Cancer.
    Urol Int. 2017 Dec 1. pii: 000479187. doi: 10.1159/000479187.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: